Clinical Trials Browser

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Phase 2 Study

Esophageal Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Lung Neoplasms

Breast Neoplasms

Gallbladder Neoplasms, Cholangiocarcinoma

Stomach Neoplasms

Locally Advanced Pancreatic Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Lung Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Pancreatic Neoplasms

Pathologic Complete Response, Head and Neck Neoplasms

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

Metastatic Squamous Non-Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Brain Neoplasms, Breast Neoplasms

Hypopharyngeal Neoplasms

Pancreatic Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Renal Pelvic Carcinoma

Clinical Stage IVB Gastric Cancer AJCC v8

Pancreatic Neoplasms

Pancreatic Neoplasms

Esophageal Neoplasms

Esophageal Neoplasms

Pancreatic Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Ureteral Neoplasms

Pancreatic Adenocarcinoma

Pancreatic Cancer Metastatic

Pancreatic Neoplasms

Breast Neoplasms

Biliary Tract Neoplasms

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms

Breast Neoplasms

Clinical Trials

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

STELLAR01

LAP100

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

PRISM-TNBC

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

LUNG-IST-127

NOVOCURE

Endosurgery-02

SOLARA

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

HARBOR

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

GENTIS

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

ATRiBRAVE

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

PTCA199-11

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

BRE-10

TAB-2

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC